[Blood pressure effects of potent GLP-1 and GIP analogues]

More on GLP-1 and incretin signalling

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026

• Low-carb telemedicine links to fewer cardiovascular events

  Cardiology and Therapy · 4 Oct 2026

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026